KR20170010019A - 방사선 및 화학적 손상으로부터 보호하기 위한 세코이솔라리시레시놀 디글루코사이드(ｓｄｇ) 및 관련 화합물의 용도 - Google Patents

방사선 및 화학적 손상으로부터 보호하기 위한 세코이솔라리시레시놀 디글루코사이드(ｓｄｇ) 및 관련 화합물의 용도 Download PDF

Info

Publication number
KR20170010019A
KR20170010019A KR1020167037042A KR20167037042A KR20170010019A KR 20170010019 A KR20170010019 A KR 20170010019A KR 1020167037042 A KR1020167037042 A KR 1020167037042A KR 20167037042 A KR20167037042 A KR 20167037042A KR 20170010019 A KR20170010019 A KR 20170010019A
Authority
KR
South Korea
Prior art keywords
sdg
exposed
subject
radiation
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167037042A
Other languages
English (en)
Korean (ko)
Inventor
멜포 크리스토피도-솔로미도
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실베니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실베니아
Publication of KR20170010019A publication Critical patent/KR20170010019A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
KR1020167037042A 2014-05-30 2015-06-01 방사선 및 화학적 손상으로부터 보호하기 위한 세코이솔라리시레시놀 디글루코사이드(ｓｄｇ) 및 관련 화합물의 용도 Withdrawn KR20170010019A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462005330P 2014-05-30 2014-05-30
US62/005,330 2014-05-30
US201562101296P 2015-01-08 2015-01-08
US62/101,296 2015-01-08
PCT/US2015/033501 WO2015184441A2 (en) 2014-05-30 2015-06-01 USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION AND CHEMICAL DAMAGE

Publications (1)

Publication Number Publication Date
KR20170010019A true KR20170010019A (ko) 2017-01-25

Family

ID=54700083

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167037042A Withdrawn KR20170010019A (ko) 2014-05-30 2015-06-01 방사선 및 화학적 손상으로부터 보호하기 위한 세코이솔라리시레시놀 디글루코사이드(ｓｄｇ) 및 관련 화합물의 용도

Country Status (9)

Country Link
EP (1) EP3148560A4 (enExample)
JP (2) JP2017520620A (enExample)
KR (1) KR20170010019A (enExample)
CN (2) CN107155304A (enExample)
AU (2) AU2015266614A1 (enExample)
CA (1) CA2950744A1 (enExample)
IL (1) IL249219A0 (enExample)
MA (1) MA39899A (enExample)
WO (1) WO2015184441A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11071746B2 (en) 2016-06-07 2021-07-27 The Trustees Of The University Of Pennsylvania Compositions and methods for protecting organs from ischemia/reperfusion injury associated with transplantation
EP3606325B1 (en) * 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
US20200268779A1 (en) * 2017-09-27 2020-08-27 The Trustees Of The University Of Pennsylvania USE OF SECOISOLARICIRESINOL DIGLUCOSIDES (SDGs) AND RELATED COMPOUNDS FOR PROTECTION AGAINST RADIATION-INDUCED CARDIOVASCULAR DYSFUNCTION
US20210128596A1 (en) * 2017-09-27 2021-05-06 University Of Pennsylvania Compositions and methods for treating septic cardiomyopathy
EP3843557B1 (en) * 2018-08-31 2023-09-20 Innophos, LLC An extract of anacardium occidentale for use in treating oxidation induced dna damage
CN116850162A (zh) * 2023-08-08 2023-10-10 南通大学附属医院 肠二醇在制备治疗放射性肠炎药物中的应用
CN121094806B (zh) * 2025-11-07 2026-02-24 深圳鼎智通讯股份有限公司 一种Android SoftPOS可信应用方法以及应用系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6486126B1 (en) * 1999-06-30 2002-11-26 University Of Saskatchewan Technologies Incorporated Antioxidant activity in SDG metabolites
EP1414436A1 (en) * 2000-06-14 2004-05-06 Alla Shapiro Radioprotective agents
CN100365005C (zh) * 2006-03-02 2008-01-30 江南大学 一种从亚麻籽中提取纯化开环异落叶松树脂酚二葡萄糖苷的方法
US20070293458A1 (en) * 2006-06-16 2007-12-20 Ip-6 Research Inc. Prevention of nuclear, solar, and other radiation-induced tissue damage
US10449224B2 (en) * 2007-05-25 2019-10-22 The Trustees Of The University Of Pennsylvania Flaxseed lignan complex, methods of using and compositions thereof
AU2009279676C1 (en) * 2008-08-07 2015-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Radioprotectants targeting thrombospondin-1 and CD47
CN101759731B (zh) * 2008-12-25 2011-10-19 中国科学院兰州化学物理研究所 亚麻籽胶和开环异落叶松树脂酚二葡萄糖苷的提取方法
PT3007557T (pt) * 2013-06-10 2018-11-09 Scripps Research Inst Preparação do diglucosídeo (s,s)-secoisolariciresinol e do diglucosídeo (r,r)-secoisolariciresinol

Also Published As

Publication number Publication date
EP3148560A2 (en) 2017-04-05
AU2015266614A1 (en) 2016-12-15
WO2015184441A3 (en) 2016-03-10
CA2950744A1 (en) 2015-12-03
CN112336736A (zh) 2021-02-09
AU2020270469A1 (en) 2020-12-17
JP2017520620A (ja) 2017-07-27
WO2015184441A9 (en) 2016-01-21
MA39899A (fr) 2021-05-26
EP3148560A4 (en) 2018-04-25
WO2015184441A2 (en) 2015-12-03
CN107155304A (zh) 2017-09-12
JP2020121987A (ja) 2020-08-13
IL249219A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
KR20170010019A (ko) 방사선 및 화학적 손상으로부터 보호하기 위한 세코이솔라리시레시놀 디글루코사이드(ｓｄｇ) 및 관련 화합물의 용도
Zhou et al. Rhein regulates redox‐mediated activation of NLRP3 inflammasomes in intestinal inflammation through macrophage‐activated crosstalk
de Jonge et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway
Li et al. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC
Wang et al. Parkin overexpression attenuates Aβ-induced mitochondrial dysfunction in HEK293 cells by restoring impaired mitophagy
Guo et al. Aluminum-induced suppression of testosterone through nitric oxide production in male mice
JP7612763B2 (ja) 癌治療
US10966995B2 (en) Use of secoisolariciresinol diglucosides (SDGS) and related compounds for protection against radiation and chemical damage
EP3220908B1 (en) Compositions and methods for treating endometriosis
Wang et al. Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy
EP3866786B1 (en) Compositions and methods for suppressing and/or treating metabolic diseases and/or a clinical condition thereof
Zheng et al. Sleep deprivation induces gut damage via ferroptosis
Sun et al. Targeting MCL1 with Sanggenon C overcomes MCL1-driven adaptive chemoresistance via dysregulation of autophagy and endoplasmic reticulum stress in cervical cancer
Yuan et al. Acetylshikonin induces apoptosis through the endoplasmic reticulum stress‐activated PERK/eIF2α/CHOP axis in oesophageal squamous cell carcinoma
US20120022129A1 (en) Targeting of Histone Deacetylase 2, Protein Kinase CK2, and Nuclear Factor NRF2 For Treatment of Inflammatory Diseases
WO2020102529A1 (en) Electrophiles and electrophile pro-drugs as rad51 inhibitors
Ma et al. Penicillamine ameliorates intestinal barrier damage in dextran sulfate sodium-induced experimental colitis mice by inhibiting cuproptosis
US10688105B2 (en) Method of treating refractory rheumatoid arthritis associated with p53 mutation
WO2015164716A1 (en) Methods for the diagnosis and treatment of pulmonary fibrosis in subjects with hermansky pudlak syndrome
WO2023192918A2 (en) Anti-oncogenic phytochemicals and methods and uses for treating cancer
HK1240082A1 (en) Use of secoisolariciresinol diglucosides (sdgs) and related compounds for protection against radiation and chemical damage
WO2023133414A2 (en) Selective elimination of senescent cells by ferroptosis induction
Li et al. Synthesis and radioprotective effects of novel hybrid compounds containing edaravone analogue and 3‐n‐butylphthalide ring‐opening derivatives
CA3117152A1 (en) Identification of ppm1d mutations as a novel biomarker for nampti sensitivity
EP3846797A1 (en) Use of delta-tocotrienol for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20161230

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination